Psyence Biomedical (PBM) News Today $2.56 -0.03 (-0.97%) As of 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Psyence Biomedical Ltd. (PBM) Achieves Breakthrough in High-Purity Ibogaine ProductionSeptember 2 at 5:46 AM | finance.yahoo.comPsyence Biomedical (NASDAQ:PBM) Stock Price Down 5.4% - What's Next?August 30, 2025 | americanbankingnews.comPsyence Biomedical (NASDAQ:PBM) Trading Down 5.4% - Here's WhyAugust 30, 2025 | americanbankingnews.comPsyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025August 28, 2025 | globenewswire.comPsyence Biomedical Ltd. (PBM) Stock Price Today - WSJAugust 5, 2025 | wsj.comPsyence Biomedical stock soars after partner achieves ibogaine breakthroughAugust 1, 2025 | za.investing.comPsyence Biomedical Shares Soar 70% Following Partner’s Ibogaine Extraction BreakthroughAugust 1, 2025 | msn.comPsyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31, 2025 | financialpost.comFPsyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31, 2025 | globenewswire.comPSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesJune 25, 2025 | globenewswire.comPsyence Biomedical regains Nasdaq compliance after reverse splitJune 18, 2025 | investing.comPSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common SharesJune 18, 2025 | globenewswire.comPsyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsJune 17, 2025 | finanznachrichten.deCVS Sues Arkansas Over Law Banning PBM Ownership Of PharmaciesMay 29, 2025 | forbes.comPsyence Biomedical Ltd. WtMay 21, 2025 | marketwatch.comPsyence Biomedical Advances Psilocybin Drug Development as of May 2025May 20, 2025 | tipranks.comPsyence Biomedical announces reverse stock splitMay 2, 2025 | investing.comPsyence BioMed gets Nasdaq notice for non-complianceApril 18, 2025 | msn.comPsyence Group Inc.: Psyence Group Announces Share ConsolidationApril 17, 2025 | finanznachrichten.dePsyence Group Announces Share ConsolidationApril 17, 2025 | globenewswire.comPsyence Biomedical reports corporate updateApril 3, 2025 | investing.comPsyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical TrialsApril 1, 2025 | tipranks.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. SteinMarch 25, 2025 | markets.businessinsider.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.March 10, 2025 | globenewswire.comPsyence Biomedical files $75M mixed securities shelfMarch 4, 2025 | markets.businessinsider.comPsyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory BoardFebruary 26, 2025 | markets.businessinsider.comPsyence Biomed Names Albert P. Garcia-Romeu, Ph.D.February 26, 2025 | globenewswire.comPsyence Biomedical files to sell 3.075M common shares for holdersJanuary 25, 2025 | markets.businessinsider.comPsyence Biomedical Issues Pre-Funded Share Purchase WarrantJanuary 1, 2025 | markets.businessinsider.comPsyence Biomed Announces Closing of $2.0 Million Private PlacementDecember 27, 2024 | globenewswire.comPsyence Biomedical prices 1M shares at $2.00 in private placementDecember 24, 2024 | markets.businessinsider.comPsyence Biomedical Regains Nasdaq Compliance, Fortifying Market PositionDecember 23, 2024 | tipranks.comPsyence Biomedical regains full compliance with Nasdaq requirementsDecember 23, 2024 | markets.businessinsider.comPsyence Biomedical Ltd.: Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing RequirementsDecember 23, 2024 | finanznachrichten.dePsyence Unveils Private PlacementDecember 23, 2024 | baystreet.caPsyence Biomed Announces $2.0 Million Private PlacementDecember 23, 2024 | tmcnet.comPsyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing RequirementsDecember 23, 2024 | globenewswire.comPsyence Biomedical files to sell 10.9M shares of common stock for holdersDecember 22, 2024 | markets.businessinsider.comPsyence Biomedical Advances in Phase IIb Psilocybin Clinical TrialDecember 20, 2024 | markets.businessinsider.comPsyence Biomedical Signs Exclusive Licensing Agreement with Optimi HealthDecember 20, 2024 | markets.businessinsider.comPsyence Biomedical Ltd.: Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialDecember 17, 2024 | finanznachrichten.dePsyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialDecember 17, 2024 | globenewswire.comCVS's Sell-Off May Be OverblownDecember 15, 2024 | seekingalpha.comPsyence Biomed Executes Binding Agreements with Optimi Health Corp.December 10, 2024 | globenewswire.comPsyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligationsDecember 6, 2024 | globenewswire.comPsyence Biomedical Boosts Equity to Meet Nasdaq RulesDecember 4, 2024 | markets.businessinsider.comPsyence Biomedical Revises Debt-for-Equity DealDecember 4, 2024 | markets.businessinsider.comPsyence Biomedical Issues Shareholder Update Highlighting Recent ProgressDecember 3, 2024 | globenewswire.comPsyence Biomedical (NASDAQ:PBM) Trading Down 7% - Time to Sell?November 27, 2024 | marketbeat.comPsyence announces favorable result on Nasdaq listing qualifications hearingNovember 21, 2024 | markets.businessinsider.com Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBM Media Mentions By Week PBM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBM News Sentiment▼-0.250.71▲Average Medical News Sentiment PBM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBM Articles This Week▼41▲PBM Articles Average Week Get the Latest News and Ratings for PBM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Psyence Biomedical and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Allarity Therapeutics News Natural Alternatives International News Cingulate News NanoViricides News Passage Bio News Citius Pharmaceuticals News Q32 Bio News Lisata Therapeutics News Relmada Therapeutics News Aytu BioPharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBM) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBM Stock Alerts